Literature DB >> 17108051

HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein.

Mayumi Nakagawa1, Kevin H Kim, Tiffany M Gillam, Anna-Barbara Moscicki.   

Abstract

One of the critical steps in the progression to cervical cancer appears to be the establishment of persistent human papillomavirus (HPV) infection. We have demonstrated that the lack of cytotoxic T-lymphocyte response to HPV type 16 (HPV 16) E6 protein was associated with persistence and that the potential presence of dominant CD8 T-cell epitopes was most frequently found (n = 4 of 23) in the E6 16-40 region by examining the pattern of CD8 T-cell epitopes within the E6 protein in women who had cleared their HPV 16 infections. The goal of this study was to define the minimal/optimal amino acid sequences and the HLA restricting molecules of these dominant CD8 T-cell epitopes as well as those of subdominant ones if present. Three dominant epitopes, E6 29-38 (TIHDIILECV; restricted by the HLA-A0201 molecule), E6 29-37 (TIHDIILEC; restricted by B48), and E6 31-38 (HDIILECV; restricted by B4002), and one subdominant epitope, E6 52-61 (FAFRDLCIVY; restricted by B35) were characterized. Taken together with a previously described dominant epitope, E6 52-61 (FAFRDLCIVY; restricted by B57), the CD8 T-cell epitopes demonstrated striking HLA class I binding promiscuity. All of these epitopes were endogenously processed, but the presence of only two of the five epitopes could have been predicted based on the known binding motifs. The HLA class I promiscuity which has been described for human immunodeficiency virus may be more common than previously recognized.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108051      PMCID: PMC1797519          DOI: 10.1128/JVI.01768-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

Review 1.  Hierarchies of antigen-specific cytotoxic T-cell responses.

Authors:  A Gallimore; H Hengartner; R Zinkernagel
Journal:  Immunol Rev       Date:  1998-08       Impact factor: 12.988

Review 2.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

3.  Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes.

Authors:  E M Evans; S Man; A S Evans; L K Borysiewicz
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

4.  Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.

Authors:  M Alexander; M L Salgaller; E Celis; A Sette; W A Barnes; S A Rosenberg; M A Steller
Journal:  Am J Obstet Gynecol       Date:  1996-12       Impact factor: 8.661

5.  Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.

Authors:  M Nakagawa; D P Stites; S Farhat; J R Sisler; B Moss; F Kong; A B Moscicki; J M Palefsky
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

6.  Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16.

Authors:  A K Sarkar; G Tortolero-Luna; P N Nehete; R B Arlinghaus; M F Mitchell; K J Sastry
Journal:  Viral Immunol       Date:  1995       Impact factor: 2.257

7.  A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

Authors:  L K Borysiewicz; A Fiander; M Nimako; S Man; G W Wilkinson; D Westmoreland; A S Evans; M Adams; S N Stacey; M E Boursnell; E Rutherford; J K Hickling; S C Inglis
Journal:  Lancet       Date:  1996-06-01       Impact factor: 79.321

8.  Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.

Authors:  E Sadovnikova; X Zhu; S M Collins; J Zhou; K Vousden; L Crawford; P Beverley; H J Stauss
Journal:  Int Immunol       Date:  1994-02       Impact factor: 4.823

9.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.

Authors:  M E Ressing; A Sette; R M Brandt; J Ruppert; P A Wentworth; M Hartman; C Oseroff; H M Grey; C J Melief; W M Kast
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

10.  Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.

Authors:  M E Boursnell; E Rutherford; J K Hickling; E A Rollinson; A J Munro; N Rolley; C S McLean; L K Borysiewicz; K Vousden; S C Inglis
Journal:  Vaccine       Date:  1996-11       Impact factor: 3.641

View more
  25 in total

1.  Use of interferon-γ enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus.

Authors:  Xuelian Wang; William W Greenfield; Hannah N Coleman; Lindsey E James; Mayumi Nakagawa
Journal:  J Vis Exp       Date:  2012-03-08       Impact factor: 1.355

2.  A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot.

Authors:  Hannah N Coleman; Xuelian Wang; William W Greenfield; Mayumi Nakagawa
Journal:  MOJ Immunol       Date:  2014

Review 3.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

4.  The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Chunqing Luo; Ron Shapiro; Diana Metes; Geetha Chalasani; Parmjeet S Randhawa
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

5.  A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.

Authors:  Angelika B Riemer; Derin B Keskin; Guanglan Zhang; Maris Handley; Karen S Anderson; Vladimir Brusic; Bruce Reinhold; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2010-07-08       Impact factor: 5.157

6.  Development of an epitope panel for consistent identification of antigen-specific T-cells in humans.

Authors:  Andreas Fløe; Caroline Løppke; Ole Hilberg; Christian Wejse; Liselotte Brix; Kivin Jacobsen
Journal:  Immunology       Date:  2017-07-03       Impact factor: 7.397

7.  Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses.

Authors:  Rebecca Axelsson-Robertson; Frank Weichold; Donata Sizemore; Markus Wulf; Yasir A W Skeiky; Jerry Sadoff; Markus J Maeurer
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

8.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

9.  Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.

Authors:  Xuelian Wang; Anna-Barbara Moscicki; Laura Tsang; Andrea Brockman; Mayumi Nakagawa
Journal:  Clin Vaccine Immunol       Date:  2008-04-30

10.  A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells.

Authors:  Xuelian Wang; Alessandro D Santin; Stefania Bellone; Sushil Gupta; Mayumi Nakagawa
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.